Stock Track | Novavax Plummets 5% as Vaccine Skeptic Kennedy Nominated to Lead Health Agency

Stock Track11-15

On Friday morning, Novavax Inc. (NVAX) shares plummeted over 5% during premarket trading amid concerns over President-elect Donald Trump's decision to nominate Robert F. Kennedy Jr., a well-known vaccine skeptic, to lead the Department of Health and Human Services (HHS).

The appointment of Kennedy, who has spread misinformation about vaccines and criticized federal health agencies, sent shockwaves through the vaccine industry. Shares of other vaccine makers, including Moderna Inc. (MRNA), BioNTech SE (BNTX), and Pfizer Inc. (PFE), also declined as investors worried about the potential impact on the sector under Kennedy's leadership.

Analysts expressed uncertainty about Kennedy's specific policy proposals and priorities for healthcare and the pharmaceutical industry. However, his track record as an outspoken critic of childhood vaccinations and his nonprofit's opposition to vaccine mandates have raised concerns about the future of vaccine programs and the broader public health landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment